• IBRANCE has a convenient, once daily, oral regimen.

• The recommended starting dose is 125 mg of IBRANCE once daily for 21 consecutive days followed by 7 days off treatment (schedule 3/1) to comprise a complete cycle of 28 days.¹
• IBRANCE should be given in combination with either an AI, or in combination with fulvestrant in women who have received prior endocrine therapy
• When co-administered with IBRANCE, the AI should be administered according to the dose schedule reported in the SmPC.
• When co-administered with IBRANCE, the recommended dose of fulvestrant is 500 mg administered intramuscularly on Days 1, 15, 29, and once monthly thereafter. Please refer to the SmPC of fulvestrant.
• In pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist.
• For patients with severe hepatic impairment (Child-Pugh class C), the recommended dose of IBRANCE is 75 mg once daily on Schedule 3/1
• Treatment with IBRANCE should be continued as long as the patient is deriving clinical benefit from therapy or until unacceptable toxicity occurs.¹

IBRANCE 125 mg (starting dose) once daily PO with or without food

Patients with absolute neutrophil counts of ≥1000/mm³ and platelet counts of ≥50,000/mm³ are recommended to receive IBRANCE¹

Patients should be encouraged to take their dose at approximately the same time each day. If the patient vomits or misses a dose, an additional dose should not be taken that day. The next prescribed dose should be taken at the usual time.

IBRANCE can be taken with or without food. IBRANCE should be swallowed whole, not chewed, crushed or split prior to swallowing.¹

As with all medications, IBRANCE may interact with certain drugs.